A detailed history of Decheng Capital Management Iii (Cayman), LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Decheng Capital Management Iii (Cayman), LLC holds 869,790 shares of RCUS stock, worth $13.8 Million. This represents 8.64% of its overall portfolio holdings.

Number of Shares
869,790
Previous 869,790 -0.0%
Holding current value
$13.8 Million
Previous $17.7 Million 11.62%
% of portfolio
8.64%
Previous 9.36%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

BUY
$17.62 - $23.54 $15.3 Million - $20.5 Million
869,790 New
869,790 $15.6 Million
Q1 2022

May 10, 2022

BUY
$28.92 - $41.83 $25.2 Million - $36.4 Million
869,790 New
869,790 $27.5 Million

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.15B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Decheng Capital Management Iii (Cayman), LLC Portfolio

Follow Decheng Capital Management Iii (Cayman), LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Decheng Capital Management Iii (Cayman), LLC, based on Form 13F filings with the SEC.

News

Stay updated on Decheng Capital Management Iii (Cayman), LLC with notifications on news.